JP2012516856A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516856A5 JP2012516856A5 JP2011548431A JP2011548431A JP2012516856A5 JP 2012516856 A5 JP2012516856 A5 JP 2012516856A5 JP 2011548431 A JP2011548431 A JP 2011548431A JP 2011548431 A JP2011548431 A JP 2011548431A JP 2012516856 A5 JP2012516856 A5 JP 2012516856A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- inhibitor
- pharmaceutical combination
- antisense oligonucleotide
- cardiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 29
- 230000002401 inhibitory effect Effects 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 24
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 9
- 229920000272 Oligonucleotide Polymers 0.000 claims 9
- 239000000074 antisense oligonucleotide Substances 0.000 claims 9
- 230000000747 cardiac effect Effects 0.000 claims 8
- 230000004048 modification Effects 0.000 claims 5
- 238000006011 modification reaction Methods 0.000 claims 5
- 230000037327 stress response Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 210000004027 cells Anatomy 0.000 claims 2
- 230000000295 complement Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 206010007554 Cardiac failure Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010019280 Heart failure Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 208000010125 Myocardial Infarction Diseases 0.000 claims 1
- 210000004413 Myocytes, Cardiac Anatomy 0.000 claims 1
- 210000002317 cardiac myocyte Anatomy 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000002064 heart cell Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000001575 pathological Effects 0.000 claims 1
Claims (21)
- ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤およびｍｉＲ−４９９の阻害剤を含む、心臓ストレス応答を低下することが必要な対象において心臓ストレス応答を低下するための医薬の組み合わせであって、前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤および前記ｍｉＲ−４９９の阻害剤を連続してまたは同時に投与し、前記阻害剤投与の２週間以内に前記対象において心臓ストレス応答が低下する、医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤および前記ｍｉＲ−４９９の阻害剤が、アンチセンスオリゴヌクレオチドである、請求項１に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤が、配列番号５または配列番号１９に対して少なくとも部分的に相補的である配列を含むアンチセンスオリゴヌクレオチドである、請求項１または２に記載の医薬の組み合わせ。
- 前記ｍｉＲ−４９９の阻害剤が、配列番号１４に対して少なくとも部分的に相補的である配列を含むアンチセンスオリゴヌクレオチドである、請求項１〜３のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂアンチセンスオリゴヌクレオチドおよび前記ｍｉＲ−４９９アンチセンスオリゴヌクレオチドが、少なくとも１つの糖および／または骨格修飾を含む、請求項２〜４のいずれか１項に記載の医薬の組み合わせ。
- 前記少なくとも１つの糖修飾が、ロックド核酸、２’−Ｏ−アルキル修飾、または２’−フルオロ修飾である、請求項５に記載の医薬の組み合わせ。
- 前記少なくとも１つの骨格修飾が、ホスホロチオエート結合である、請求項５または６に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂアンチセンスオリゴヌクレオチドおよび前記ｍｉＲ−４９９アンチセンスオリゴヌクレオチドが、約８〜約１８ヌクレオチド長である、請求項２〜７のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂアンチセンスオリゴヌクレオチドおよび前記ｍｉＲ−４９９アンチセンスオリゴヌクレオチドが、約１２〜約１６ヌクレオチド長である、請求項２〜７のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８の阻害剤および前記ｍｉＲ−４９９の阻害剤が別々の組成物中に存在する、請求項１〜９のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤および前記ｍｉＲ−４９９の阻害剤が連続して投与される、請求項１〜１０のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤が前記ｍｉＲ−４９９の阻害剤の前に投与される、請求項１１に記載の医薬の組み合わせ。
- 前記ｍｉＲ−４９９の阻害剤が前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤の前に投与される、請求項１１に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤および前記ｍｉＲ−４９９の阻害剤が少なくとも２４時間離れて投与される、請求項１１〜１３のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８の阻害剤および前記ｍｉＲ−４９９の阻害剤が同じ組成物中に存在する、請求項１〜９のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤および前記ｍｉＲ−４９９の阻害剤が発現ベクターによってコードされる、請求項１〜４のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤および前記ｍｉＲ−４９９の阻害剤が、同じ発現ベクターによってコードされている、請求項１６に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂの阻害剤および前記ｍｉＲ−４９９の阻害剤が、約１ｍｇ／ｋｇ〜約２００ｍｇ／ｋｇの用量で投与される、請求項１〜１７のいずれか１項に記載の医薬の組み合わせ。
- 前記ｍｉＲ−２０８ａまたはｍｉＲ−２０８ｂおよび前記ｍｉＲ−４９９の発現または活性が、前記阻害剤の投与後に前記対象の心臓細胞において６０パーセント低下する、請求項１〜１８のいずれか１項に記載の医薬の組み合わせ。
- 前記心臓ストレス応答が、心筋細胞肥大、心臓繊維症、心臓細胞におけるα−ＭＨＣ発現の低下、および／または前記対象の心臓細胞におけるβ−ＭＨＣ発現の増大を含む、請求項１〜１９のいずれか１項に記載の医薬の組み合わせ。
- 前記対象は、病的な心臓肥大、心不全、または心筋梗塞を発症する危険性がある、請求項１〜２０のいずれか１項に記載の医薬の組み合わせ。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14991509P | 2009-02-04 | 2009-02-04 | |
| US61/149,915 | 2009-02-04 | ||
| PCT/US2010/023234 WO2010091204A1 (en) | 2009-02-04 | 2010-02-04 | Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012516856A JP2012516856A (ja) | 2012-07-26 |
| JP2012516856A5 true JP2012516856A5 (ja) | 2013-03-21 |
| JP5943608B2 JP5943608B2 (ja) | 2016-07-05 |
Family
ID=42542383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548431A Expired - Fee Related JP5943608B2 (ja) | 2009-02-04 | 2010-02-04 | 心臓障害の治療におけるｍｉｒ−２０８およびｍｉｒ−４９９の二重ターゲティング |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8629119B2 (ja) |
| EP (1) | EP2393945A4 (ja) |
| JP (1) | JP5943608B2 (ja) |
| KR (1) | KR20110128838A (ja) |
| CN (1) | CN102356162A (ja) |
| AU (1) | AU2010210605B2 (ja) |
| BR (1) | BRPI1008517A2 (ja) |
| CA (1) | CA2751489A1 (ja) |
| MX (1) | MX2011008190A (ja) |
| NZ (1) | NZ594365A (ja) |
| RU (1) | RU2515926C2 (ja) |
| UA (1) | UA105029C2 (ja) |
| WO (1) | WO2010091204A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5995855B2 (ja) | 2010-11-05 | 2016-09-21 | ミラゲン セラピューティクス，インコーポレイテッド | 塩基修飾オリゴヌクレオチド |
| AU2011343720A1 (en) * | 2010-12-15 | 2013-04-11 | Miragen Therapeutics | MicroRNA inhibitors comprising locked nucleotides |
| JP2014507123A (ja) * | 2010-12-15 | 2014-03-27 | ミラゲン セラピューティクス | 心臓病状に対する薬効のサロゲートマーカーとしての血中ｍｉＲＮＡ |
| EP2763703B1 (en) | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Control of whole body energy homeostasis by microrna regulation |
| EP2584040A1 (en) | 2011-10-17 | 2013-04-24 | Pharmahungary 2000 Kft. | Compounds for treatment of ischemic injury |
| CA2876180C (en) | 2012-06-21 | 2019-11-19 | MiRagen Therapeutics, Inc. | Oligonucleotide-based inhibitors comprising locked nucleic acid motif |
| CN102980920A (zh) * | 2012-11-14 | 2013-03-20 | 华东师范大学 | 同时检测miRNAs与蛋白标记物的硅纳米线芯片及其检测方法和应用 |
| CN105154445B (zh) * | 2014-06-12 | 2018-07-27 | 中国科学院上海生命科学研究院 | 新的肌营养不良肌病的血清miRNA标志物 |
| US9752144B2 (en) * | 2014-08-04 | 2017-09-05 | MiRagen Therapeutics, Inc. | Inhibitors of MYH7B and uses thereof |
| AU2016209386A1 (en) | 2015-01-20 | 2017-08-03 | MiRagen Therapeutics, Inc. | miR-92 inhibitors and uses thereof |
| LT3283508T (lt) | 2015-04-17 | 2021-07-12 | Alpine Immune Sciences, Inc. | Imunomoduliuojantys baltymai su sureguliuojamu giminingumu |
| AU2016270434B2 (en) * | 2015-06-05 | 2019-07-11 | MiRagen Therapeutics, Inc. | miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL) |
| CA3198255A1 (en) | 2017-10-10 | 2019-04-18 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| CN108815535B (zh) * | 2018-08-08 | 2020-05-19 | 哈尔滨医科大学 | 一种抗心肌肌钙蛋白抗体修饰并载有miR-21的脂质体及其制备方法和应用 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001280889A1 (en) | 2000-07-31 | 2002-02-13 | Gene Logic, Inc. | Molecular toxicology modeling |
| KR20030034177A (ko) * | 2000-09-13 | 2003-05-01 | 쥬가이 세이야쿠 가부시키가이샤 | 허혈성 질환 치료제 |
| IL156137A0 (en) * | 2000-12-07 | 2003-12-23 | Gencell Sa | Sequences upstream of the carp gene, vectors containing them and uses thereof |
| US20050124568A1 (en) | 2001-05-18 | 2005-06-09 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA) |
| US6964950B2 (en) * | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
| WO2003029459A2 (en) | 2001-09-28 | 2003-04-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Micro-rna molecules |
| EP1578393A4 (en) | 2002-02-04 | 2008-03-19 | Gene Logic Inc | MODELING THE TOXICITY OF PRIMARY RAT-BASED RAT CELLS |
| US20080214437A1 (en) | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US7781415B2 (en) | 2003-02-07 | 2010-08-24 | Roche Madison Inc. | Process for delivering sirna to cardiac muscle tissue |
| CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| WO2005047505A2 (en) | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
| WO2005017145A1 (ja) | 2003-08-13 | 2005-02-24 | Japan Biological Informatics Consortium | 機能性ｒｎａが制御する被制御遺伝子の同定・予測方法及びその利用方法 |
| US20050256072A1 (en) | 2004-02-09 | 2005-11-17 | University Of Massachusetts | Dual functional oligonucleotides for use in repressing mutant gene expression |
| WO2005078139A2 (en) | 2004-02-09 | 2005-08-25 | Thomas Jefferson University | DIAGNOSIS AND TREATMENT OF CANCERS WITH MicroRNA LOCATED IN OR NEAR CANCER-ASSOCIATED CHROMOSOMAL FEATURES |
| US7772389B2 (en) | 2004-02-13 | 2010-08-10 | Rockefeller University | Anti-microRNA oligonucleotide molecules |
| EP2471922A1 (en) | 2004-05-28 | 2012-07-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| WO2006013561A2 (en) | 2004-08-02 | 2006-02-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for diagnosing and treating post traumatic stress disorder |
| JP2006101790A (ja) | 2004-10-06 | 2006-04-20 | Japan Health Science Foundation | 高血圧症のリスクの評価方法 |
| WO2006047454A2 (en) | 2004-10-21 | 2006-05-04 | Rutgers, The State University Of New Jersey | Rational probe optimization for detection of micrornas |
| EP2322616A1 (en) | 2004-11-12 | 2011-05-18 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| WO2006063356A1 (en) | 2004-12-10 | 2006-06-15 | Isis Phamaceuticals, Inc. | Regulation of epigenetic control of gene expression |
| US20060185027A1 (en) | 2004-12-23 | 2006-08-17 | David Bartel | Systems and methods for identifying miRNA targets and for altering miRNA and target expression |
| US20070099196A1 (en) | 2004-12-29 | 2007-05-03 | Sakari Kauppinen | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs |
| US8071306B2 (en) | 2005-01-25 | 2011-12-06 | Merck Sharp & Dohme Corp. | Methods for quantitating small RNA molecules |
| WO2006111512A1 (en) | 2005-04-19 | 2006-10-26 | Basf Plant Science Gmbh | Improved methods controlling gene expression |
| CA2609142C (en) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
| WO2007035684A2 (en) | 2005-09-16 | 2007-03-29 | Primera Biosystems, Inc. | Method for quantitative detection of short rna molecules |
| US20070092882A1 (en) | 2005-10-21 | 2007-04-26 | Hui Wang | Analysis of microRNA |
| NZ569738A (en) | 2005-12-12 | 2012-03-30 | Univ North Carolina | MicroRNAs (miRNA) that regulate muscle cell proliferation and differentiation |
| US20100286044A1 (en) | 2005-12-29 | 2010-11-11 | Exiqon A/S | Detection of tissue origin of cancer |
| US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
| CA3024953A1 (en) | 2006-04-03 | 2007-10-11 | Roche Innovation Center Copenhagen A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
| PL2056882T3 (pl) | 2006-08-01 | 2013-03-29 | Univ Texas | Identyfikacja mikro-RNA, który aktywuje ekspresję łańcucha ciężkiego beta-miozyny |
| WO2008042231A2 (en) | 2006-09-29 | 2008-04-10 | Children's Medical Center Corporation | Compositions and methods for evaluating and treating heart failure |
| WO2008043521A2 (de) | 2006-10-09 | 2008-04-17 | Julius-Maximilians-Universität Würzburg | Microrna (mirna) zur diagnose und therapie von herzerkrankungen |
| JP2010509923A (ja) | 2006-11-23 | 2010-04-02 | ミルクス セラピューティクス アンパーツゼルスカブ | 標的ｒｎａの活性を変化させるためのオリゴヌクレオチド |
| WO2008076324A2 (en) * | 2006-12-14 | 2008-06-26 | Novartis Ag | Compositions and methods to treat muscular & cardiovascular disorders |
| EP3536788A1 (en) | 2006-12-21 | 2019-09-11 | QIAGEN GmbH | Microrna target site blocking oligos and uses thereof |
| WO2008074328A2 (en) | 2006-12-21 | 2008-06-26 | Exiqon A/S | Microrna target site blocking oligos and uses thereof |
| CA2687336C (en) | 2007-05-23 | 2014-12-23 | Dharmacon, Inc. | Micro-rna scaffolds and non-naturally occurring micro-rnas |
| MX2010001216A (es) * | 2007-07-31 | 2010-04-30 | Univ Texas | Microarn que controla la expresion de miosina y la identidad de miofibras. |
| WO2009026576A1 (en) | 2007-08-23 | 2009-02-26 | Keren Pharmaceuticals | Targeting rna with external guide sequences |
| AU2008306327B2 (en) | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
| WO2009058818A2 (en) | 2007-10-29 | 2009-05-07 | The Board Of Regents Of The University Of Texas System | Compositions comprising a micro-rna and methods of their use in regulating cardiac remodeling |
| MX2010005166A (es) | 2007-11-09 | 2010-10-07 | Univ Texas | Micro arn de la familia mir-15 que modulan la sobrevivencia de cardiomiocitos y reparacion cardiaca. |
| WO2009114681A2 (en) | 2008-03-13 | 2009-09-17 | Dharmacon, Inc. | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| US20090326049A1 (en) | 2008-04-04 | 2009-12-31 | Alexander Aristarkhov | Blocking oligos for inhibition of microrna and sirna activity and uses thereof |
| WO2009149182A1 (en) | 2008-06-04 | 2009-12-10 | The Board Of Regents Of The University Of Texas System | Modulation of gene expression through endogenous small rna targeting of gene promoters |
| AU2009257663B2 (en) | 2008-06-09 | 2014-06-26 | New York Medical College | Compositions comprising cardiac stem cells overexpressing specific microRNA and methods of their use in repairing damaged myocardium |
| EP2447274B1 (en) | 2008-10-24 | 2017-10-04 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
-
2010
- 2010-02-04 US US13/147,784 patent/US8629119B2/en not_active Expired - Fee Related
- 2010-02-04 EP EP20100739137 patent/EP2393945A4/en not_active Withdrawn
- 2010-02-04 WO PCT/US2010/023234 patent/WO2010091204A1/en active Application Filing
- 2010-02-04 JP JP2011548431A patent/JP5943608B2/ja not_active Expired - Fee Related
- 2010-02-04 RU RU2011136640/10A patent/RU2515926C2/ru not_active IP Right Cessation
- 2010-02-04 UA UAA201110646A patent/UA105029C2/uk unknown
- 2010-02-04 AU AU2010210605A patent/AU2010210605B2/en not_active Ceased
- 2010-02-04 CN CN2010800123730A patent/CN102356162A/zh active Pending
- 2010-02-04 NZ NZ59436510A patent/NZ594365A/xx not_active IP Right Cessation
- 2010-02-04 CA CA 2751489 patent/CA2751489A1/en not_active Abandoned
- 2010-02-04 MX MX2011008190A patent/MX2011008190A/es active IP Right Grant
- 2010-02-04 BR BRPI1008517A patent/BRPI1008517A2/pt not_active IP Right Cessation
- 2010-02-04 KR KR20117020396A patent/KR20110128838A/ko not_active Application Discontinuation
-
2013
- 2013-12-12 US US14/104,886 patent/US20140179764A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012516856A5 (ja) | ||
| CN103282497B (zh) | 使用短干扰核酸(siNA)的乙型肝炎病毒(HBV)基因表达的RNA干扰介导的抑制 | |
| US8871731B2 (en) | Micro-RNA for the regulation of cardiac apoptosis and contractile function | |
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| JP2012029693A5 (ja) | ||
| EP2552454B1 (en) | ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS | |
| TWI607016B (zh) | 微型ｒｎａ化合物及調控ｍｉｒ－２１活性之方法 | |
| SI2929031T1 (en) | PCSK9 IRNA assemblies and procedures for their use | |
| US9163235B2 (en) | Inhibitors of the miR-15 family of micro-RNAs | |
| JP2011500858A5 (ja) | ||
| JP2017505623A5 (ja) | ||
| JP2018536689A5 (ja) | ||
| JP2014504857A5 (ja) | ||
| JP2012510297A5 (ja) | ||
| JP2011092201A5 (ja) | ||
| JP2014527401A5 (ja) | ||
| JP2012130342A5 (ja) | ||
| JP2011528333A5 (ja) | ||
| RU2015127794A (ru) | Введение антисмысловых олигонуклеотидов, комплементарных человеческому аполипопротеину в | |
| JP2016517888A5 (ja) | ||
| JP2014509852A5 (ja) | ||
| JP2016520310A5 (ja) | ||
| JP2011225596A5 (ja) | ||
| BR112015024764B1 (pt) | Oligonucleotídeos de tgf-beta modificados, seu uso e composições farmacêuticas que os compreendem | |
| JP2014503192A5 (ja) |